A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP).
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2017
At a glance
- Drugs MMR-varicella zoster virus vaccine (Primary)
- Indications Measles; Mumps; Rubella; Varicella zoster virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Merck & Co; Merck Sharp & Dohme
- 11 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 30 Apr 2013 Planned End Date changed from 1 Feb 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 30 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.